A Study of Apatinib Treatment in for Advanced Ovarian Cancer

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The study is evaluated the effacy and safety of apatinib combined with chemotherapy in the advanced ovarian cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The People's Hospital of Leshan
• Collaborator: Jiangsu HengRui Medicine Co., Ltd.
• Treatments: Apatinib

Criteria

Inclusion Criteria:

• Pathologically diagnosed as epithelial ovarian cancer, fallopian tube cancer, stage II-IV period, the expected survival of> 6 months;

• ECOG <2;

• Liver and kidney function is normal;

• No uncontrollable high blood pressure, bleeding, perforation, obstruction.

Exclusion Criteria:

• Serious cardiopulmonary insufficiency, can not tolerate chemotherapy;

• Pregnant or lactating women;

• 3 years have occurred in other tumors (cervical cancer in situ, has cured basal cell carcinoma, except for bladder epithelial tumors);

• Allergic to apatinib or its accessories.